Head-To-Head Contrast: Galena Biopharma (GALE) & The Competition

Galena Biopharma (NASDAQ: GALE) is one of 116 public companies in the “Pharmaceuticals” industry, but how does it compare to its peers? We will compare Galena Biopharma to related businesses based on the strength of its earnings, risk, dividends, institutional ownership, profitability, analyst recommendations and valuation.

Insider & Institutional Ownership

20.5% of Galena Biopharma shares are owned by institutional investors. Comparatively, 43.6% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 0.8% of Galena Biopharma shares are owned by company insiders. Comparatively, 11.8% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Galena Biopharma and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Galena Biopharma 0 2 0 0 2.00
Galena Biopharma Competitors 824 3701 6736 182 2.55

Galena Biopharma presently has a consensus target price of $4.00, suggesting a potential upside of 937.34%. As a group, “Pharmaceuticals” companies have a potential upside of 23.34%. Given Galena Biopharma’s higher probable upside, equities research analysts plainly believe Galena Biopharma is more favorable than its peers.

Valuation and Earnings

This table compares Galena Biopharma and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Galena Biopharma N/A -$23.48 million -0.22
Galena Biopharma Competitors $8.20 billion $2.68 billion -1.31

Galena Biopharma’s peers have higher revenue and earnings than Galena Biopharma. Galena Biopharma is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.


This table compares Galena Biopharma and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Galena Biopharma N/A -76.75% -28.16%
Galena Biopharma Competitors -2,882.52% -64.06% -9.02%

Risk and Volatility

Galena Biopharma has a beta of 1.82, suggesting that its share price is 82% more volatile than the S&P 500. Comparatively, Galena Biopharma’s peers have a beta of 0.90, suggesting that their average share price is 10% less volatile than the S&P 500.


Galena Biopharma peers beat Galena Biopharma on 9 of the 12 factors compared.

Galena Biopharma Company Profile

Galena Biopharma, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company’s development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company’s NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company’s therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient’s own immune system to seek out and attack any residual cancer cells.

Receive News & Ratings for Galena Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galena Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply